Literature DB >> 10773946

Oral deferiprone--controversies on its efficacy and safety.

V P Choudhry1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 10773946     DOI： 10.1007/bf02831341

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN： 0019-5456            Impact factor:   1.967


× No keyword cloud information.
  9 in total

1.  Deferiprone (L1) associated neutropenia in beta thalassemia major: an Indian experience.

Authors:  H P Pati; V P Choudhry
Journal:  Eur J Haematol       Date:  1999-10       Impact factor: 2.997

2.  Long-term assessment of efficacy and safety of L1, an oral iron chelator, in transfusion dependent thalassaemia: Indian trial.

Authors:  M B Agarwal; S S Gupte; C Viswanathan; D Vasandani; J Ramanathan; N Desai; R R Puniyani; A T Chhablani
Journal:  Br J Haematol       Date:  1992-10       Impact factor: 6.998

Review 3.  Current management of homozygous beta thalassemia.

Authors:  V P Choudhry; N Desai; H P Pati; A Nanu
Journal:  Indian Pediatr       Date:  1991-10       Impact factor: 1.411

Review 4.  Oral iron chelation.

Authors:  A V Hoffbrand
Journal:  Semin Hematol       Date:  1996-01       Impact factor: 3.851

Review 5.  Oral iron chelation with deferiprone.

Authors:  O Diav-Citrin; G Koren
Journal:  Pediatr Clin North Am       Date:  1997-02       Impact factor: 3.278

6.  Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients.

Authors:  A V Hoffbrand; F AL-Refaie; B Davis; N Siritanakatkul; B F Jackson; J Cochrane; E Prescott; B Wonke
Journal:  Blood       Date:  1998-01-01       Impact factor: 22.113

7.  Iron-chelation therapy with oral deferiprone in patients with thalassemia major.

Authors:  N F Olivieri; G M Brittenham; D Matsui; M Berkovitch; L M Blendis; R G Cameron; R A McClelland; P P Liu; D M Templeton; G Koren
Journal:  N Engl J Med       Date:  1995-04-06       Impact factor: 91.245

8.  Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major.

Authors:  N F Olivieri; G M Brittenham; C E McLaren; D M Templeton; R G Cameron; R A McClelland; A D Burt; K A Fleming
Journal:  N Engl J Med       Date:  1998-08-13       Impact factor: 91.245

9.  Oral iron chelating therapy. A single center interim report on deferiprone (L1) in thalassemia.

Authors:  P Mazza; B Amurri; G Lazzari; C Masi; G Palazzo; M A Spartera; R Giua; A M Sebastio; V Suma; S De Marco; F Semeraro; R Moscogiuri
Journal:  Haematologica       Date:  1998-06       Impact factor: 9.941
  9 in total
  1 in total

Review 1.  Past, present & future scenario of thalassaemic care & control in India.

Authors:  Ishwar C Verma; Renu Saxena; Sudha Kohli
Journal:  Indian J Med Res       Date:  2011-10       Impact factor: 2.375
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.